In the treatment of chronic kidney disease (CKD), reducing proteinuria and improving kidney function are central goals that play a crucial role in preventing progression to end-stage renal disease (ESRD).
Over the past several decades, the medical community has continuously explored and discovered multiple medications with significant therapeutic effects on kidney disease, successfully applying them in clinical practice. These medications have broad applications, covering virtually all types of kidney diseases.
The 8 Key Medications:
1. ACE Inhibitors (ACEi) – Generic names ending in “-pril” (e.g., lisinopril, enalapril), commonly used for blood pressure control.
2. Angiotensin Receptor Blockers (ARBs) – Generic names ending in “-sartan” (e.g., losartan, valsartan), also used for hypertension management.
3. SGLT-2 Inhibitors – Generic names ending in “-gliflozin” (e.g., empagliflozin, dapagliflozin), originally developed for diabetes management.
4. Mineralocorticoid Receptor Antagonists (MRAs) – Currently includes spironolactone, eplerenone, and finerenone. These can function as diuretics and are also classified as antihypertensive agents.
5. Vitamin D – Patients with impaired kidney function typically use active vitamin D analogues, such as calcitriol or paricalcitol.
6. Statin Medications – Primarily used for lipid management and cardiovascular protection.
7. Fish Oil (Omega-3 Fatty Acids) – Also used for lipid regulation, distinct from fish liver oil supplements.
8. Herbal Supplements – While cordyceps preparations are popular in some regions, their evidence base is limited in Western medicine, so they are not routinely recommended in standard American practice.
Common Characteristics
These medications share several important features:
- Disease-agnostic efficacy: They provide benefits across all types of kidney diseases
- Manageable side effect profiles: Generally well-tolerated with controllable adverse effects
- Broad applicability: Unlike immunosuppressants, steroids, or targeted therapies that work only for specific kidney diseases
However, “universal” also implies limitations. While these medications can slow disease progression and are particularly effective for mild cases, they serve primarily as adjunctive therapy for patients with advanced disease.
For patients with mild elevations in creatinine and proteinuria, these supportive medications often provide adequate control. However, when indicators reach moderate to severe levels (proteinuria >1g/day, creatinine >150 μmol/L or >1.7 mg/dL), achieving treatment goals (such as reducing proteinuria to <0.5g/day) requires addressing underlying causes with more specific, intensive treatments.
Effectiveness Rankings
For Proteinuria Reduction:
ACEi = ARBs ≥ SGLT-2i ≈ Spironolactone/Finerenone ≈ Statins > Vitamin D > Fish Oil
Specifically:
- First tier: ACEi/ARBs (at high doses), SGLT-2 inhibitors, spironolactone/finerenone, and statins can reduce proteinuria by approximately 50%
- Second tier: Vitamin D reduces proteinuria by about 20%, comparable to standard-dose ACEi/ARBs
- Third tier: Fish oil and herbal supplements show variable results, with only some patients experiencing proteinuria reduction
For Kidney Function Protection:
SGLT-2i > ACEi = ARBs > Finerenone > Spironolactone ≈ Statins
SGLT-2 inhibitors lead the field, followed closely by ACEi/ARBs. These medication classes have been proven in large-scale randomized controlled trials to provide kidney protection and have received FDA approval with guideline recommendations for this indication.
Current Evidence Status:
- SGLT-2 inhibitors and ACEi/ARBs: Strong evidence base with proven kidney protection
- Finerenone: Emerging evidence as a newer agent with promising results, though more long-term data are needed
- Spironolactone and statins: Limited evidence from smaller studies; not yet established as foundational CKD therapies
- Vitamin D, fish oil: No conclusive evidence for preventing or delaying kidney failure, though they may have other benefits
Clinical Recommendations
Currently, kidney protection strategies center around “ACEi/ARBs + SGLT-2 inhibitors” as the foundation, with their proteinuria-reducing effects being additive. Future protocols may include finerenone as part of a triple-combination approach.
Important Considerations
Reducing proteinuria ≠ Kidney benefit: Not every medication that lowers proteinuria necessarily provides long-term kidney protection. Some treatments may have other effects that counteract the benefits of proteinuria reduction.
When selecting treatments, clinicians must consider not only proteinuria reduction but also long-term kidney function outcomes. The goal is meaningful disease modification, not simply “improving” laboratory values.
Key Takeaway
The principle that “universal means universally limited” remains applicable in nephrology today. For mild cases, these medications often appear “universal” in their effectiveness. However, for moderate to severe proteinuria, nephrotic syndrome, or advanced kidney disease, these medications often prove inadequate, requiring specialized, cause-specific treatments to meaningfully alter disease progression.
Clinical Bottom Line
These eight medication classes represent important tools in the nephrologist’s armamentarium, but they work best as part of comprehensive care plans that address underlying disease mechanisms, cardiovascular risk factors, and individual patient needs. For patients with kidney disease, working closely with a nephrologist ensures optimal use of these therapies within evidence-based treatment protocols.
Note: This information is for educational purposes only and should not replace consultation with qualified healthcare providers. Treatment decisions should always be individualized based on specific patient circumstances and current clinical guidelines.
发表回复